Trial reportClinical transplantation
Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients.
Trial report in Clinical transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Steroid avoidance or withdrawal for kidney transplant recipients.The Cochrane database of systematic reviews · 2026Pooled it
- Steroid avoidance or withdrawal for kidney transplant recipients.The Cochrane database of systematic reviews · 2016Pooled it
- Impact of corticosteroid withdrawal on bone mineral density after kidney transplantation.Aging clinical and experimental research · 2025Article
- Kidney Transplantation, Immunosuppression and the Risk of Fracture: Clinical and Economic Implications.Kidney medicine · 2022Article
- Relationship of abdominal aortic calcification with lumbar vertebral volumetric bone mineral density assessed by quantitative computed tomography in maintenance hemodialysis patients.Archives of osteoporosis · 2022Article
- Factors Related to Bone Metabolism in Kidney Transplant Recipients.Mediators of inflammation · 2021Article
- Mineral and Bone Disease in Kidney Transplant Recipients.Current osteoporosis reports · 2018Review
- Article
- Metabolic consequences of modern immunosuppressive agents in solid organ transplantation.Therapeutic advances in endocrinology and metabolism · 2016Review
- Mineral and bone disorder after kidney transplantation.World journal of transplantation · 2015Review
- Structural and mechanical repair of diffuse damage in cortical bone in vivo.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2014Article
- The role of imaging in patient selection, preoperative planning, and postoperative monitoring in human upper extremity allotransplantation.Journal of transplantation · 2014Article
- Reduced fracture risk with early corticosteroid withdrawal after kidney transplant.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Glucocorticoid (GC) therapy induces deleterious effects on the skeleton in kidney transplantation but studies of GC discontinuation in this population are limited. This study evaluated changes in areal bone mineral density (BMD) with GC withdrawal. Subjects were enrolled one yr after renal transplantation and randomized to continue or stop prednisone; all subjects continued cyclosporine and mycophenolate mofetil. BMD measured by dual-energy X-ray absorptiometry was performed at enrollment and repeated at one yr and values were standardized. Mean ± standard deviation of annualized change in standardized BMD between GC withdrawal vs. continuation group at the lumbar spine was +4.7% ± 5.5 vs. +0.9% ± 5.3 (p = 0.0014); total hip +2.4% ± 4.2 vs. -0.4% ± 4.2 (p = 0.013), and femoral neck +2.1% ± 4.6 vs. +1.0% ± 6.0 (p = 0.37). There was no confounding by prednisone dose prior to enrollment, change in creatinine clearance, weight, or use of bone-active medications following study entry. Multivariate analysis determined that the change in BMD was positively associated with baseline alkaline phosphatase and creatinine clearance and negatively associated with baseline BMD. BMD improves with GC withdrawal after renal transplantation, and this gain in BMD is dependent on the baseline bone turnover, renal function, and BMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.